Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutelyagitated patients diagnosed with bipolar mania
Autore:
Meehan, K; Zhang, F; David, S; Tohen, M; Janicak, P; Small, J; Koch, K; Rizk, R; Walker, D; Tran, P; Breier, A;
Indirizzi:
Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USAEli Lilly & Co Indianapolis IN USA 46285 Labs, Indianapolis, IN 46285 USA Univ Illinois, Dept Psychiat, Chicago, IL 60680 USA Univ Illinois ChicagoIL USA 60680 , Dept Psychiat, Chicago, IL 60680 USA Larue D Carter Mem Hosp, Div Mental Hlth, Indianapolis, IN USA Larue D Carter Mem Hosp Indianapolis IN USA l Hlth, Indianapolis, IN USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 4, volume: 21, anno: 2001,
pagine: 389 - 397
SICI:
0271-0749(200108)21:4<389:ADRCOT>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
IM OLANZAPINE; RATING-SCALE; SCHIZOPHRENIA; PHARMACOKINETICS; AGGRESSION; PSYCHOSIS; VALIDITY; DISORDER; PANSS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Breier, A Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN46285 USA Eli Lilly & Co Indianapolis IN USA 46285 anapolis, IN 46285 USA
Citazione:
K. Meehan et al., "A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutelyagitated patients diagnosed with bipolar mania", J CL PSYCH, 21(4), 2001, pp. 389-397

Abstract

There are no rapid-acting intramuscular formulations of atypical antipsychotics available for quickly calming an agitated patient with bipolar disorder. In this study, 201 agitated patients with bipolar mania were randomly assigned to receive one to three injections of the atypical antipsychotic olanzapine (10 mg, first two injections; 5 mg, third injection), the benzodiazepine lorazepam (2 mg, first two injections; 1 mg, third injection), or placebo (placebo, first two injections; olanzapine, 10 mg, third injection) within a 24-hour period. Agitation was measured at baseline, every 30 minutes for the first 2 hours, and at 24 hours after the first injection using the Positive and Negative Syndrome Scale-Excited Component subscale and two additional agitation scales. At 2 hours after the first injection, patients treated with olanzapine showed a significantly greater reduction in scores on all agitation scales compared with patients treated with either placebo or lorazepam. At 24 hours after the first injection, olanzapine remained statistically superior to placebo in reducing agitation in patients with acute mania, whereas patients treated with lorazepam were not significantly different from those treated with placebo or olanzapine. Furthermore, no significant differences among the three treatment groups were observed in safetymeasures, including treatment-emergent extrapyramidal symptoms, the incidence of acute dystonia, or QTc interval changes. These findings suggest thatintramuscular olanzapine is a safe and effective treatment for reducing acute agitation in patients with bipolar mania.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 03:05:37